- Home
- SDSTW vs QLGN Comparison
SDSTW vs QLGN Comparison
Compare SDSTW & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDSTW
- QLGN
- Stock Information
- Founded
- SDSTW N/A
- QLGN 1996
- Country
- SDSTW United States
- QLGN United States
- Employees
- SDSTW 8
- QLGN N/A
- Industry
- SDSTW
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SDSTW
- QLGN Health Care
- Exchange
- SDSTW Nasdaq
- QLGN Nasdaq
- Market Cap
- SDSTW 3.7M
- QLGN 3.1M
- IPO Year
- SDSTW N/A
- QLGN N/A
- Fundamental
- Price
- SDSTW $0.07
- QLGN $1.90
- Analyst Decision
- SDSTW
- QLGN
- Analyst Count
- SDSTW 0
- QLGN 0
- Target Price
- SDSTW N/A
- QLGN N/A
- AVG Volume (30 Days)
- SDSTW 41.6K
- QLGN 125.5K
- Earning Date
- SDSTW 03-26-2025
- QLGN 08-26-2025
- Dividend Yield
- SDSTW N/A
- QLGN N/A
- EPS Growth
- SDSTW N/A
- QLGN N/A
- EPS
- SDSTW N/A
- QLGN N/A
- Revenue
- SDSTW N/A
- QLGN N/A
- Revenue This Year
- SDSTW N/A
- QLGN N/A
- Revenue Next Year
- SDSTW N/A
- QLGN N/A
- P/E Ratio
- SDSTW N/A
- QLGN N/A
- Revenue Growth
- SDSTW N/A
- QLGN N/A
- 52 Week Low
- SDSTW $0.10
- QLGN $1.61
- 52 Week High
- SDSTW $0.12
- QLGN $11.50
- Technical
- Relative Strength Index (RSI)
- SDSTW N/A
- QLGN 32.76
- Support Level
- SDSTW N/A
- QLGN $1.61
- Resistance Level
- SDSTW N/A
- QLGN $1.91
- Average True Range (ATR)
- SDSTW 0.00
- QLGN 0.16
- MACD
- SDSTW 0.00
- QLGN -0.01
- Stochastic Oscillator
- SDSTW 0.00
- QLGN 26.48
About SDSTW Stardust Power Inc. Warrant
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.